Related Experiment Video
Updated: Oct 21, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
[Risk of cirrhosis in chronic viral hepatitis patients]
M Latournerie1, O Coatmeur1, P Hillon1
1Hépatogastroentérologie, Hôpital du Bocage, 2 bd Maréchal de Lattre de Tassigny, BP 77 908, 21079 Dijon Cedex.
Abstract:
The risk of cirrhosis in HCV and HBV-related liver diseases is higher in males than in females ; it increases exponentially after the age of 40 for the two genders. Alcohol consumption exceeding 50 gr per day multiplies cirrhosis risk by 6.0 in HBV patients and by 2.4 in HCV patients. B and C virus liver-related diseases are worsened by HIV co-infection particularly in patients with CD4 count lower than 200 per ml. Steatosis due to high body mass index (BMI) and/or metabolic syndrome is a newly described risk factor for cirrhosis in HBV and HCV patients and for hepatocellular carcinoma in HCV patients. Steatosis may become in a near future one of the major predicting factors of severity for chronic liver disease. The knowledge of worsening factors in patients suffering from chronic B and C viral hepatitis must lead clinicians to consider specific therapeutics against these factors and antiviral treatment even in case of borderline indication.
Related Concept Videos
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Esophageal Varices-I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

